cabergoline / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 66 Diseases   17 Trials   17 Trials   1476 News 


«12345678910111213...1617»
  • ||||||||||  cabergoline / Generic mfg., bromocriptine / Generic mfg.
    Retrospective data, Review, Journal:  Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis. (Pubmed Central) -  Nov 17, 2023   
    This study shows that dopamine 2 agonists significantly lowered FBS and HbA1c levels without causing severe negative effects. Even though the results are promising, additional research is necessary to establish the appropriate antihyperglycemic dosage, frequency of daily use, side effects, and potential product interactions when employing dopamine 2 receptor agonists for their antihyperglycemic effect.
  • ||||||||||  cabergoline / Generic mfg.
    Preclinical, Journal:  Effects of cabergoline and dimethylcabergoline on the sexual behavior of male rats. (Pubmed Central) -  Nov 16, 2023   
    Both CAB and DMC facilitate ejaculations, and CAB further facilitates measures of anticipatory sexual motivation and intromissions. These data suggest that both could be used as treatments for sexual arousal disorders and ejaculation/orgasm disorders with little or no untoward side effects at low doses.
  • ||||||||||  Signifor (pasireotide) / Recordati, Metopirone (metyrapone) / HRA Pharma, Isturisa (osilodrostat) / Novartis, Recordati
    Journal, Surgery:  Discontinuation of drug treatment in Cushing's disease not cured by pituitary surgery. (Pubmed Central) -  Nov 14, 2023   
    Interestingly, a successful 2nd TSS was the cause for discontinuing efficient and well tolerated DT in 5 patients. Further studies will show whether different strategies with cortisol synthesis inhibitors may allow for a lower discontinuation rate in patients not candidates for a 2nd TSS, so that BA may be avoided in these patients.
  • ||||||||||  cabergoline / Generic mfg.
    Preclinical, Journal:  Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats. (Pubmed Central) -  Nov 4, 2023   
    Further studies will show whether different strategies with cortisol synthesis inhibitors may allow for a lower discontinuation rate in patients not candidates for a 2nd TSS, so that BA may be avoided in these patients. Aflibercept, an antiangiogenic medication, decreased ovarian hyperstimulation syndrome by lowering the vascular permeability and vascular endothelial growth factor expression.
  • ||||||||||  cabergoline / Generic mfg., bromocriptine / Generic mfg.
    The D2R-SSTR5 heterodimer in pituitary neuroendocrine tumors and its functional crosstalk. (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_10583;    
    Furthermore, the detection of D2R-SSTR5 heterodimer in PitNET samples suggests that SSTR5 may play a regulatory role in the D2R signaling pathway within pituitary tumors through heterodimerization with D2R. By elucidating the interplay between SSTR5 and D2R, this research offers valuable information that can guide the design of future therapeutic interventions for PitNET.
  • ||||||||||  cabergoline / Generic mfg., bromocriptine / Generic mfg.
    Journal:  Succ (Pubmed Central) -  Oct 22, 2023   
    Bromocriptine was established as disease specific therapy; less data is known about Cabergolin which is another prolactin secretion inhibitor. In this paper we report 4 peripartum cardiomyopathy cases treated successfully with Cabergoline, including a cardiogenic shock case requiring mechanical circulatory support.
  • ||||||||||  cabergoline / Generic mfg.
    A RARE CASE OF THYROTROPIN?SECRETING PITUITARY ADENOMA: PRESENTATION AND MANAGEMENT () -  Sep 20, 2023 - Abstract #ATA2023ATA_366;    
    He was treated with octreotide and cabergoline...The alpha?GSU/TSH molar ratio is elevated in 50?85% of macroadenoma and is used to assess therapy efficacy only in these cases. The most sensitive and specific test for cure is the T3 suppression test but has limited use due to many contraindications.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal, HEOR, Real-world evidence, Adherence, Real-world:  Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis. (Pubmed Central) -  Sep 14, 2023   
    Patients with more comorbidities had more health care visits during the first year after diagnosis, suggesting increased disease burden. Real-world evidence on treatment patterns provides insights into recommendations for individualized therapy.
  • ||||||||||  cabergoline / Generic mfg., ketamine / Generic mfg., levetiracetam / Generic mfg.
    Preclinical, Journal:  The link between seizures and prolactin: A study on the effects of anticonvulsant medications on hyperprolactinemia in rats. (Pubmed Central) -  Aug 28, 2023   
    Drying off by reducing the energy density of the diet caused behavioral changes indicative of hunger before dry-off, whereas reducing the milking frequency had no clear effects on behavior. The study involved 30 adult female Wistar rats, which were divided into a control group (treated with normal saline) and four treatment groups: chronic group (treated with 30
  • ||||||||||  cabergoline / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  Cabergoline for the Treatment of Chronic Pain Due to Endometriosis (clinicaltrials.gov) -  Aug 2, 2023   
    P2,  N=140, Recruiting, 
    CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients. N=80 --> 140 | Trial completion date: Jun 2023 --> Aug 2024 | Trial primary completion date: Jun 2023 --> Aug 2024
  • ||||||||||  cabergoline / Generic mfg.
    Journal:  Neuroimaging of Pituitary Neuroendocrine Tumors (Pubmed Central) -  Jul 25, 2023   
    In somatotroph PitNETs, the signal intensity on T2WI is important to differentiate densely granulated tumors from sparsely granulated somatotroph tumors. In lactotroph PitNETs, distinct hypointense areas in the early phase on T2WI, possibly due to diffuse hemorrhage, indicate pronounced regression of invasive macroprolactinomas during cabergoline therapy.
  • ||||||||||  cabergoline / Generic mfg., carbidopa/levodopa / Generic mfg.
    Late-Onset Symptomatic Hyperprolactinemia in 6-Pyruvoyl-Tetrahydropterin Synthase Deficiency (Exhibitions Hall (ICC)) -  Jul 11, 2023 - Abstract #SSIEM2023SSIEM_494;    
    Cabergoline is an effective and well-tolerated strategy to prevent breast symptoms after second-trimester abortion or pregnancy loss. Thirteen patients (7 females and 6 males) with PTPS deficiency diagnosed by newborn screening and currently aged 23.5
  • ||||||||||  cabergoline / Generic mfg.
    Poor outcomes of Laser Hair Reduction in Patients with Hyperprolactenemia - a 100 case series () -  Jul 3, 2023 - Abstract #WCD2023WCD_3827;    
    Hyper prolactin states which are known to up regulate MSH are known to influence reactivation of progenitor stem cells in hair bulb and bulge responsible for poor laser hair responses. The retrospective study of this large series of hyperprolactinemia patients in India highlights cautious enrollment of these patients for laser hair reduction
  • ||||||||||  cabergoline / Generic mfg., hydrocortisone / Generic mfg.
    Journal:  Diagnosis and management of pituitary apoplexy: a Tunisian data. (Pubmed Central) -  Jul 1, 2023   
    To conclude, pituitary apoplexy is a challenging condition due to its variable course, its diagnosis difficulty and management, as gaps remain to determine the best approach to treat this condition. Further studies are thus needed.
  • ||||||||||  SNJ-1656 / Senju, Novartis, Omlonti (omidenepag isopropyl) / Santen, Ube Industries, AMA0076 / Peak Bio
    Review, Journal:  Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment. (Pubmed Central) -  Jun 19, 2023   
    However, translation of the novel animal-based findings to the human conditions remains to be demonstrated but represent viable targets, especially EP-receptor agonists (e.g. omidenepag isopropyl; AL-6598; butaprost), mixed activity serotonin/dopamine receptor agonists (e.g. cabergoline), rho kinase inhibitors (e.g. AMA0076, Y39983), CACNA2D1-gene product inhibitors (e.g. pregabalin), melatonin receptor agonists, and certain K-channel openers (e.g. nicorandil, pinacidil). Other drug candidates and targets were also identified and will be discussed.
  • ||||||||||  cabergoline / Generic mfg.
    Journal:  Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study. (Pubmed Central) -  May 31, 2023   
    In group A, only insulin resistance, hsCRP, and homocysteine were reduced by cabergoline. The effects on insulin sensitivity, HDL-cholesterol, triglycerides, hsCRP, fibrinogen, homocysteine, uric acid, and UACR were proportional to the decrease in prolactin and baseline levels of 25-hydroxyvitamin D. The obtained results suggest that vitamin D status determines cabergoline's cardiometabolic effects.
  • ||||||||||  Trial completion date, Trial primary completion date:  Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia. (clinicaltrials.gov) -  May 23, 2023   
    P1,  N=100, Completed, 
    The effects on insulin sensitivity, HDL-cholesterol, triglycerides, hsCRP, fibrinogen, homocysteine, uric acid, and UACR were proportional to the decrease in prolactin and baseline levels of 25-hydroxyvitamin D. The obtained results suggest that vitamin D status determines cabergoline's cardiometabolic effects. Trial completion date: Dec 2020 --> May 2023 | Trial primary completion date: Sep 2020 --> Jan 2023
  • ||||||||||  cabergoline / Generic mfg., temozolomide / Generic mfg., bromocriptine / Generic mfg.
    Journal:  Italian Guidelines for the Management of Prolactinomas. (Pubmed Central) -  May 12, 2023   
    Our findings suggest that only cabergoline reduces cardiometabolic risk in young women with hyperprolactinemia. The present GL is directed to endocrinologists, neurosurgeons, and gynecologists working in hospitals, in territorial services or private practice, and to general practitioners and patients.
  • ||||||||||  cabergoline / Generic mfg., hydrocortisone / Generic mfg., desmopressin / Generic mfg.
    Diabetes Insipidus - pituitary apoplexy or placental vasopressinase? (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2037;    
    Apoplexy in pregnancy is very rare, occurring only in 1 in 10,000 gestations. The clinical presentation in this case suggests a low threshold to order pituitary imaging in cases presenting with concerning sign symptoms of increase intracranial pressure.
  • ||||||||||  cabergoline / Generic mfg.
    Prolactinoma Recurrence with Testosterone Treatment in Transgender Male (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2013;    
    Introduction We present a case of recurrent hyperprolactinemia due to testosterone treatment for gender-affirming hormonal therapy in a transgender male after being controlled on cabergoline for more than a year...Hyperprolactinemia in this setting is resistant to dopamine agonist therapy, as noted in multiple case reports.There are no established reference ranges for PRL levels for transgender patients on gender-affirming hormone therapy and no current guidelines regarding routine imaging or biochemical assessment during follow-up. Transgender patients with prolactinoma may require additional treatment with non-aromatizable androgens or the concomitant administration of aromatase inhibitors.
  • ||||||||||  cabergoline / Generic mfg.
    Lack Of Tumor Size Change With Long-term Cabergoline For Prolactinoma (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2012;    
    Fibrotic changes from long standing adenomas might be a possibility causing resistance to shrinkage of tumor, however it would be interesting to know if any specific molecular mechanisms that could be involved. In tumors with significant mass effect or those not responding to MT, Surgery is the preferred next step, and neurosurgery evaluation is necessary for further management.
  • ||||||||||  cabergoline / Generic mfg., temozolomide / Generic mfg.
    The various clinical outcomes of giant prolactinomas in men (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2010;    
    Temozolomide was introduced...Due to hyperprolactinemia, cabergoline was implemented (7mg/week)...The management of giant prolactionomas in men is challenging. Further multicenter studies to understand the pathophysiology and prognostic factors of giant prolactionomas in men are needed.